Halozyme Therapeutics (NASDAQ:HALO) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says
Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) had its price target hoisted by analysts at JPMorgan Chase & Co. from $55.00 to $58.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm currently has a “neutral” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s target price would suggest […]
More Stories
The Babysitter 3: Renewal Status, Release Date, Cast Members & Plot
Nine years after Netflix’s debut, the horror-comedy film The Babysitter remains one of the biggest hits. What began as a...
Original Games and Familiar Brands: Two Creative Routes in Online Casino Entertainment
A familiar film title can make a game recognisable before anyone opens it. An original character has a different task,...
Weather System Off North Carolina Could Become Nor’Easter or Tropical Storm: What to Know
By T.J. Muscaro The National Weather Service and its National Hurricane Center are tracking a storm system sitting off the...
Wall Street Review: Nasdaq Sinks 4.48 Percent as Inflation Fears Hit AI Stocks
By Panos Mourdoukoutas The Nasdaq Composite fell 4.48 percent for the week as hotter-than-expected inflation data sent Treasury yields higher...
Republican Attorney General Candidate New York, Saritha Komatireddy, Lays Out Her Vision
By Juliette Fairley Fresh off a fiery political debate last week, Republican challenger Saritha Komatireddy on Oct. 15 laid out...
Chaos and Violence Grip France as Far-Left Mobs Storm City Halls, Torch Streets
By Etienne Fauchaire PARIS—Stones and fireworks were already flying across Place de la République before Saturday’s demonstration against rising costs...